Education
About Us
Working with TipRanks
Follow Us
Edgewise Therapeutics (EWTX)
NASDAQ:EWTX
EWTX Stock Chart & Stats
$16.03
-$0.39(-1.54%)
At close: 4:00 PM EST
$16.03
-$0.39(-1.54%)
Day’s Range― - ―
52-Week Range$10.60 - $38.12
Previous CloseN/A
Volume107.81K
Average Volume (3M)889.10K
Market Cap
$1.60B
Enterprise Value$786.15M
Total Cash (Recent Filing)$593.99M
Total Debt (Recent Filing)$4.37M
Price to Earnings (P/E)―
Beta2.29
Next Earnings
Nov 06, 2025EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding105,345,710
10 Day Avg. Volume585,799
30 Day Avg. Volume889,098
Financial Highlights & Ratios
PEG Ratio2.41
Price to Book (P/B)5.37
Price to Sales (P/S)0.00
P/FCF Ratio-22.36
Enterprise Value/Market Cap0.49
Enterprise Value/Revenue371.18
Enterprise Value/Gross Profit-334.25
Enterprise Value/Ebitda-4.70
Forecast
1Y Price Target
$38.14Price Target Upside137.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Clinical AdvancementsBoth drug candidates have exhibited well-tolerated safety profiles, favorable functional improvements, and positive clinical outcomes, and are poised to advance toward late-stage development.
Financial PerformanceEdgewise announced financial results with EPS better than both the company's and consensus estimates.
Regulatory ApprovalSevasemten aims to become the first approved drug for Becker muscular dystrophy and an adjuvant for Duchenne muscular dystrophy standard of care.
Bears Say
Market ExpectationsLimited opportunities for significant price discovery and for the stock to re-rate based on the expected cadence of clinical and regulatory updates.
Regulatory ChallengesKey clinical and regulatory questions remain unanswered.
Stock PerformanceEWTX shares have materially underperformed following the announcement of mixed data from its HCM program.
Edgewise Therapeutics News
EWTX FAQ
What was Edgewise Therapeutics’s price range in the past 12 months?
Edgewise Therapeutics lowest stock price was $10.60 and its highest was $38.12 in the past 12 months.
What is Edgewise Therapeutics’s market cap?
Edgewise Therapeutics’s market cap is $1.60B.
When is Edgewise Therapeutics’s upcoming earnings report date?
Edgewise Therapeutics’s upcoming earnings report date is Nov 06, 2025 which is in 8 days.
How were Edgewise Therapeutics’s earnings last quarter?
Edgewise Therapeutics released its earnings results on Aug 07, 2025. The company reported -$0.34 earnings per share for the quarter, beating the consensus estimate of -$0.414 by $0.074.
Is Edgewise Therapeutics overvalued?
According to Wall Street analysts Edgewise Therapeutics’s price is currently Undervalued.
Does Edgewise Therapeutics pay dividends?
Edgewise Therapeutics does not currently pay dividends.
What is Edgewise Therapeutics’s EPS estimate?
Edgewise Therapeutics’s EPS estimate is -0.4.
How many shares outstanding does Edgewise Therapeutics have?
Edgewise Therapeutics has 105,345,710 shares outstanding.
What happened to Edgewise Therapeutics’s price movement after its last earnings report?
Edgewise Therapeutics reported an EPS of -$0.34 in its last earnings report, beating expectations of -$0.414. Following the earnings report the stock price went down -4.216%.
Which hedge fund is a major shareholder of Edgewise Therapeutics?
Currently, no hedge funds are holding shares in EWTX
Edgewise Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$38.14 (137.93% Upside)
$38.14 (137.93% Upside)
Blogger Sentiment
Bullish
EWTX Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 409.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 2.0%
Last 30 Days ▲ 2.8%
Last 30 Days ▲ 2.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-54.17%
12-Months-Change
Fundamentals
Return on Equity
-27.41%
Trailing 12-Months
Asset Growth
15.36%
Trailing 12-Months
Company Description
Edgewise Therapeutics
Edgewise Therapeutics (EWTX) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of therapies for rare muscle disorders. The company's primary aim is to address the unmet medical needs of patients with debilitating neuromuscular diseases by leveraging its proprietary drug discovery platform to develop novel, small molecule therapies. Edgewise's lead product candidates target specific genetic mutations and pathways involved in muscle dysfunction, offering potential therapeutic solutions for conditions such as Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD).
EWTX Stock 12 Month Forecast
Average Price Target
$38.14
▲(137.93% Upside)
Technical Analysis
Viridian Therapeutics
―
Pharvaris
―
Vera Therapeutics
―
Janux Therapeutics Inc
―
Biohaven Ltd.
―
Ownership Overview
1.38% Insiders
11.00% Mutual Funds
<0.01% Other Institutional Investors
78.68% Public Companies and
Individual Investors